Sorafenib off-target effects predict outcomes in patients treated for hepatocellular carcinoma
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Sorafenib off-target effects predict outcomes in patients treated for hepatocellular carcinoma
Authors
Keywords
-
Journal
Future Oncology
Volume 11, Issue 6, Pages 943-951
Publisher
Future Medicine Ltd
Online
2015-03-11
DOI
10.2217/fon.14.291
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma
- (2013) Kaoru Tsuchiya et al. CANCER
- Worse outcome of sorafenib therapy associated with ascites and Child-Pugh score in advanced hepatocellular carcinoma
- (2013) Hwi Young Kim et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Early prediction of response to sorafenib in patients with advanced hepatocellular carcinoma: The role of dynamic contrast enhanced ultrasound
- (2013) Maria Assunta Zocco et al. JOURNAL OF HEPATOLOGY
- Hepatocellular carcinoma treated with sorafenib: early detection of treatment response and major adverse events by contrast-enhanced US
- (2013) Katsutoshi Sugimoto et al. LIVER INTERNATIONAL
- Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma
- (2013) Ju-Yeon Cho et al. LIVER INTERNATIONAL
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2012) Bassam Estfan et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Molecular mechanisms of sorafenib action in liver cancer cells
- (2012) Melchiorre Cervello et al. CELL CYCLE
- Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma
- (2012) J. M. Llovet et al. CLINICAL CANCER RESEARCH
- Safety and effectiveness of sorafenib in patients with hepatocellular carcinoma in clinical practice
- (2012) Giovan Giuseppe Di Costanzo et al. DIGESTIVE AND LIVER DISEASE
- The impact of patient and tumour baseline characteristics on the overall survival of patients with advanced hepatocellular carcinoma treated with sorafenib
- (2012) Marcus A. Wörns et al. DIGESTIVE AND LIVER DISEASE
- Real-Life Clinical Practice with Sorafenib in Advanced Hepatocellular Carcinoma: A Single-Center Experience
- (2012) Masatoshi Kudo et al. DIGESTIVE DISEASES
- Diarrhea predicts a positive response to sorafenib in patients with advanced hepatocellular carcinoma
- (2012) Dominik Bettinger et al. HEPATOLOGY
- Skin toxicities and survival in advanced hepatocellular carcinoma patients treated with sorafenib
- (2012) Taiga Otsuka et al. HEPATOLOGY RESEARCH
- Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma
- (2012) Nicola Personeni et al. JOURNAL OF HEPATOLOGY
- Diarrhea Is a Positive Outcome Predictor for Sorafenib Treatment of Advanced Hepatocellular Carcinoma
- (2012) Ronald Koschny et al. ONCOLOGY
- Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score
- (2011) A. Hollebecque et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib
- (2011) M. Pinter et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma
- (2011) Julien Edeline et al. CANCER
- A single center experience of sorafenib in advanced hepatocellular carcinoma patients
- (2011) Tianqiang Song et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- Prognostic Factors in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib: A Retrospective Comparison with Previously Known Prognostic Models
- (2011) Kyung Kee Baek et al. ONCOLOGY
- Hepatocellular Carcinoma: Novel Molecular Approaches for Diagnosis, Prognosis, and Therapy
- (2010) Augusto Villanueva et al. Annual Review of Medicine
- Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma
- (2010) Yu-Yun Shao et al. CANCER
- Early Skin Toxicity as a Predictive Factor for Tumor Control in Hepatocellular Carcinoma Patients Treated with Sorafenib
- (2010) B. Vincenzi et al. ONCOLOGIST
- Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
- (2010) Riccardo Lencioni et al. SEMINARS IN LIVER DISEASE
- Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitrostudy
- (2009) Zhe Zhang et al. BMC Medicine
- Serum -Fetoprotein Response as a Surrogate for Clinical Outcome in Patients Receiving Systemic Therapy for Advanced Hepatocellular Carcinoma
- (2009) S. R. Vora et al. ONCOLOGIST
- Review article: pharmacological therapy for hepatocellular carcinoma with sorafenib and other oral agents
- (2008) M. CHAPARRO et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab
- (2008) M. Scartozzi et al. ANNALS OF ONCOLOGY
- New Utility of an Old Marker: Serial α-Fetoprotein Measurement in Predicting Radiologic Response and Survival of Patients With Hepatocellular Carcinoma Undergoing Systemic Chemotherapy
- (2008) Stephen L. Chan et al. JOURNAL OF CLINICAL ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evolving Strategies for the Management of Hand-Foot Skin Reaction Associated with the Multitargeted Kinase Inhibitors Sorafenib and Sunitinib
- (2008) M. E. Lacouture et al. ONCOLOGIST
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started